FDA Flags Data Integrity Concerns at Dabur India Facility After Inspection
Updated
Updated · Devdiscourse · May 29
FDA Flags Data Integrity Concerns at Dabur India Facility After Inspection
9 articles · Updated · Devdiscourse · May 29
U.S. FDA raised significant data integrity concerns at a Dabur India facility after a recent inspection, putting the Indian consumer health and Ayurvedic products maker under regulatory scrutiny.
The warning centers on the reliability of manufacturing data, a compliance issue that can affect product quality oversight and undermine confidence in safety controls.
Dabur is a major supplier of Ayurvedic and consumer health products, making the inspection findings notable beyond a single plant.
The case adds to a broader global health backdrop that also includes shifting drug coverage, new treatment advances and preparedness efforts for emerging infectious diseases.
With weight-loss drugs reshaping economies and health, who are the overlooked winners and losers in this medical revolution?
As funding for Africa's Ebola fight dwindles, why are foreign quarantine facilities becoming a new point of international friction?